Form 4 for SLDB Solid Biosciences Inc.
Accepted 2022-12-05 00:00:00 ET · period of report 2022-12-02 · accession 0001104659-22-124599 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2022-12-05 | 2022-12-02 | SLDB | RA CAPITAL MANAGEMENT, L.P. | Dir, 10% | A - Grant | $7.05 | +2.57M | 2.99M | +621% | +$18.14M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-02 | A | A | 109,661 | — | 109,661 | I See footnotes | — | — | (F4) Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022. (F5) Held directly by RA Capital Nexus Fund, L.P. (the "Nexus Fund"). (F6) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| 2 | Common | Common Stock | 2022-12-02 | A | A | 300,412 | — | 3,288,056 | I See footnotes | — | — | (F4) Acquired pursuant to the acquisition by the Issuer of AavantiBio, Inc. ("AavantiBio") in exchange for shares of preferred stock of AavantiBio pursuant to the Agreement and Plan of Merger dated September 29, 2022. (F2) Reflects the Issuer's reverse stock split that occurred on October 27, 2022. (F6) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). |
| 3 | Common | Common Stock | 2022-12-02 | A | A | 2,163,120 | $7.05 | 2,987,644 | I See footnotes | — | — | (F1) Acquired from the Issuer pursuant to the Securities Purchase Agreement dated September 29, 2022. (F2) Reflects the Issuer's reverse stock split that occurred on October 27, 2022. (F6) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) Held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). |